Bifidobacterium Infantis: A Long Research History, a Newer Angle
Bifidobacterium Infantis is one of the most extensively studied probiotic species, with decades of research behind it — almost all of it in infant health and digestive symptoms. Its inclusion in a weight-focused formula rests on a newer, thinner body of evidence than that long track record might suggest.
- Botanical name
- Bifidobacterium longum subsp. infantis (bacterial strain, not a plant)
- Part used
- Live bacterial culture
What it is
Bifidobacterium longum subspecies infantis is one of the dominant bacterial species in the gut of breastfed infants, where it plays a well-documented role in digesting human milk oligosaccharides — complex sugars in breast milk that infants cannot digest directly. This makes it one of the earliest and most thoroughly studied gut colonisers in the human microbiome field.
In adults, it is one of several Bifidobacterium species included in probiotic supplements generally, and it retains a research base larger than most probiotic strains, owing to its long history of study in infant and paediatric contexts.
The IBS research, and the newer metabolic angle
Outside of infant research, the most substantial adult clinical evidence for this species — often studied under the specific commercial strain designation "35624" — concerns irritable bowel syndrome. A frequently cited randomised controlled trial found that this specific strain reduced overall IBS symptom scores, including bloating and abdominal discomfort, compared to placebo over an eight-week period.
The evidence for a role in weight management specifically is considerably newer and thinner than the IBS and infant-health research. It draws on a broader body of microbiome research suggesting Bifidobacterium species generally may influence short-chain fatty acid production and gut-barrier function — mechanisms with plausible relevance to metabolic health — but dedicated, well-powered human trials measuring weight outcomes specifically for this strain are limited.
This is a common pattern across the probiotic category worth naming plainly: a strain can be extremely well studied for one thing — here, infant gut colonisation and adult IBS symptoms — while being only lightly studied for another, newer claim built on top of that established reputation. The safety record transfers across uses; the specific efficacy claim does not automatically.
Safety
What to check before taking it
- Severely weakened immune system. The same rare bloodstream-infection caution that applies to live probiotics generally; speak to a doctor first if this applies to you.
- Central venous catheter or critical illness. Hospitals commonly restrict probiotic use in these situations for the same reason.
- Currently on antibiotics. Separate dosing by a couple of hours to preserve the live culture’s viability.
Bifidobacterium infantis has one of the strongest overall safety records of any probiotic species, reflecting decades of study in infants — among the most safety-scrutinised populations in clinical research. The trial literature is searchable on PubMed.
How to read this guide
This page describes a plant and what has been studied about it. It is not advice about whether you personally should take anything. Dietary supplements are not medicines. They are not intended to diagnose, treat, cure or prevent any disease. Information on this page is for general education and does not replace advice from a doctor, pharmacist or other qualified health professional.
Talk to your doctor before starting any supplement if you take prescription medication, have a diagnosed condition, or are scheduled for surgery.